These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Case of anaphylaxis and four cases of allergic reaction following Gd-DTPA administration. Salonen OL J Comput Assist Tomogr; 1990; 14(6):912-3. PubMed ID: 2229566 [TBL] [Abstract][Full Text] [Related]
8. Fatal reaction to gadopentetate dimeglumine. Jordan RM; Mintz RD AJR Am J Roentgenol; 1995 Mar; 164(3):743-4. PubMed ID: 7863905 [No Abstract] [Full Text] [Related]
9. Pruritus and paresthesia after i.v. administration of Gd-DTPA. Chan K; Bosanko CM; Wang AM AJNR Am J Neuroradiol; 1989; 10(5 Suppl):S53. PubMed ID: 2505565 [No Abstract] [Full Text] [Related]
10. Life-threatening anaphylactoid reaction after intravenous gadoteridol administration in a patient who had previously received gadopentetate dimeglumine. Witte RJ; Anzai LL AJNR Am J Neuroradiol; 1994 Mar; 15(3):523-4. PubMed ID: 8197951 [TBL] [Abstract][Full Text] [Related]
12. [A case of anaphylactic shock following the administration of Gd-DTPA]. Nomura M; Takeshita G; Katada K; Nakamura M; Kizukuri T; Ogura Y; Anno H; Koga S Nihon Igaku Hoshasen Gakkai Zasshi; 1993 Dec; 53(12):1387-91. PubMed ID: 8108244 [TBL] [Abstract][Full Text] [Related]
13. Severe adverse reaction to iv gadopentetate dimeglumine. Takebayashi S; Sugiyama M; Nagase M; Matsubara S AJR Am J Roentgenol; 1993 Mar; 160(3):659. PubMed ID: 8430574 [No Abstract] [Full Text] [Related]
14. Safety and tolerance after intravenous administration of 0.3 mmol/kg Gd-DTPA. Results of a randomized, controlled clinical trial. Niendorf HP; Haustein J; Louton T; Beck W; Laniado M Invest Radiol; 1991 Nov; 26 Suppl 1():S221-3; discussion S232-5. PubMed ID: 1808134 [No Abstract] [Full Text] [Related]
15. Acute deterioration of myasthenia gravis after intravenous administration of gadolinium-DTPA. Nordenbo AM; Somnier FE Lancet; 1992 Nov; 340(8828):1168. PubMed ID: 1359250 [No Abstract] [Full Text] [Related]
16. Cutaneous nodules, pain, and thrombophlebitis as an adverse reaction to gadolinium contrast media. Murphy KJ; Hansen R; Prince MR AJR Am J Roentgenol; 1997 Jul; 169(1):318-9. PubMed ID: 9207574 [No Abstract] [Full Text] [Related]
17. MR contrast enhancement of intracranial lesions with Gd-DTPA. Hesselink JR; Press GA Radiol Clin North Am; 1988 Jul; 26(4):873-87. PubMed ID: 3289078 [TBL] [Abstract][Full Text] [Related]
18. Considerations in the choice of contrast media for MR imaging. Brasch RC; Bennett HF Radiology; 1988 Mar; 166(3):897-9. PubMed ID: 3340795 [No Abstract] [Full Text] [Related]
19. Can gadolinium be safely given in renal failure? Weissleder R AJR Am J Roentgenol; 1996 Jul; 167(1):278-9. PubMed ID: 8659405 [No Abstract] [Full Text] [Related]
20. Importance of a previous allergy to an iodinated contrast agent in the administration of gadopentetate dimeglumine. García N; Ramón E; Gonzalez del Valle L; Ruano M; Jiménez E Ann Pharmacother; 1997 Mar; 31(3):374. PubMed ID: 9066954 [No Abstract] [Full Text] [Related] [Next] [New Search]